PT  - JOURNAL ARTICLE
AU  - Hoertel, Nicolas
AU  - Rico, Marina Sanchez
AU  - Vernet, Raphaël
AU  - Jannot, Anne-Sophie
AU  - Neuraz, Antoine
AU  - Blanco, Carlos
AU  - Lemogne, Cédric
AU  - Airagnes, Guillaume
AU  - Paris, Nicolas
AU  - Daniel, Christel
AU  - Gramfort, Alexandre
AU  - Lemaitre, Guillaume
AU  - Bernaux, Mélodie
AU  - Bellamine, Ali
AU  - Beeker, Nathanaël
AU  - Limosin, Frédéric
AU  - ,
TI  - Observational Study of Haloperidol in Hospitalized Patients with Covid-19
AID  - 10.1101/2020.07.15.20150490
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.07.15.20150490
4099  - http://medrxiv.org/content/early/2020/07/20/2020.07.15.20150490.short
4100  - http://medrxiv.org/content/early/2020/07/20/2020.07.15.20150490.full
AB  - Background Haloperidol, a widely used antipsychotic, has been suggested as potential effective treatment for Covid-19 on the grounds of its in-vitro antiviral effects against SARS-CoV-2.Methods We examined the association between haloperidol use and respiratory failure at AP-HP Greater Paris University hospitals. Data were obtained regarding all adult patients hospitalized with Covid-19 since the beginning of the epidemic. Study baseline was defined as the date of hospital admission. The primary endpoint was a composite of intubation or death and the secondary endpoint was discharge home among survivors in time-to-event analyses. We compared outcomes between patients who were exposed to haloperidol and those who were not, using a multivariable Cox regression model with inverse probability weighting according to the propensity score.Results Of the 13,279 hospitalized adult patients with positive Covid-19 RT-PCR test, 667 patients (5.0%) were excluded because of missing data. Of the remaining 12,612 patients, 104 (0.8%) were exposed to haloperidol. Over a mean follow-up of 20.8 days, the primary endpoint of respiratory failure respectively occurred in 27 patients (26.0%) exposed to haloperidol and 1,700 patients (13.6%) who were not. Among survivors, the secondary endpoint of discharge home occurred in 26 patients (32.1%) who received haloperidol and 6,110 patients (55.3%) who did not. In the main analysis, there were no significant associations between haloperidol use and the primary (HR, 1.09; 95% CI, 0.60 to 1.97, p=0.772) and secondary (HR, 0.88; 95% CI, 0.50 to 1.53, p=0.643) endpoints. Results were similar in multiple sensitivity analyses.Conclusion In this observational study involving patients with Covid-19 who had been admitted to the hospital, haloperidol use was not associated with risk of intubation or death, or with time to hospital discharge home. These results suggest that haloperidol is unlikely to have a clinical efficacy for Covid-19.Competing Interest StatementNH has received personal fees and non-financial support from Lundbeck, outside the submitted work. FL has received speaker and consulting fees from Janssen-Cilag, Eutherapie-Servier, and Lundbeck, outside the submitted work. CL reports personal fees and non-financial support from Janssen-Cilag, Lundbeck, Otsuka Pharmaceutical, and Boehringer Ingelheim, outside the submitted work. GA reports personal fees from Pfizer, Pierre Fabre and Lundbeck, outside the submitted work. Other authors declare no competing interests.Funding StatementThis work did not receive any external funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board of the AP-HP clinical data warehouse approved this study (CSE-20-20_COVID19). All procedures related to this work adhered to the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData from the AP-HP Health Data Warehouse can be obtained at https://eds.aphp.fr//.